Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. MD Anderson Cancer Center, University of Texas, Houston, TX, United States

Survival: 14.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Houston, TX
Hospital: MD Anderson Cancer Center, University of Texas
Journal: Link
Date: 11/2010

This study involved 30 women with epithelial ovarian cancer whose cancer had progressed following prior platinum-based chemotherapy. The median patient age was 63 years.

Patients were treated with a combination of two chemotherapy agents, azacitidine and carboplatin.

The maximum toxicity level reported was grade 4, including neutropenia and thrombocytopenia. Also, 30% of patients experienced grade 3 fatigue and 13.3% reported grade 3 pain at injection site.

The median progression-free survival for this study was 3.7 months. The median overall survival was 14 months.

This study was supported by Pharmion Corp., makers of azacitidine (trade name: Vidaza).

Correspondence: Dr. Siqing Fu; email:

E-mail to a Friend Email Physician More Information